June 23

New rare disease gene therapy startup recruits former Sarepta executive as CEO

first_img Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED By Adam Feuerstein Oct. 22, 2020 Reprints @adamfeuerstein GET STARTED Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. What is it? [email protected] Log In | Learn More A three-year-old gene therapy startup from Florida is relaunching Thursday with an infusion of health care investor cash and a chief executive officer recruited from Sarepta Therapeutics.AavantiBio will use $107 million in new Series A financing to fund the development of an experimental gene therapy to treat patients with Friedreich’s Ataxia, a rare, inherited disease that causes damage to the central nervous system and heart. What’s included?center_img New rare disease gene therapy startup recruits former Sarepta executive as CEO About the Author Reprints Biotech Adam Feuerstein Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Tags biotechnologygene therapySTAT+ Adobe STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.last_img

Tags: , , , , , , , , , , ,
Copyright 2021. All rights reserved.

Posted June 23, 2021 by admin in category "ituwljvne

Leave a Reply

Your email address will not be published. Required fields are marked *